First case description of a quadruple therapy with silibinin, telaprevir, ribavirin and pegIFNα2a in a liver transplanted patient with chronic Hepatitis C Virus infection

Aims: After liver transplantation antiviral therapy of chronic Hepatitis C Virus (HCV) reinfection of the graft remains challenging. Protease inhibitor based antiviral therapy seems to improve outcome of antiviral therapy but is still limited by dependency on previous treatment outcome with standard of care (SOC). Silibinin (SIL) has already proven potent antiviral efficacy in the pre-, peri- and post-transplantation period and has been shown lately to be a direct-acting antiviral drug. Aims: To evaluate antiviral efficacy and safety of a quadruple therapy consisting of i.v. infusions of silibinin combined with…